By Daniella Parra
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) said its Enhanced Brain Delivery (EBD) bispecific antibodies showed improved brain penetration in the treatment of Alzheimer’s disease.
The company said it is collaborating with JCR Pharmaceuticals Co., Ltd. on EBD candidate development and studies through transferrin receptor-mediated delivery across both mouse and non-human primate models.
READ MORE
The Cancer Therapy Strategy VERAXA Is Betting the Company On
“Confirming our mouse data in non-human primates is a pivotal step for our EBD program,” said Paul Shughrue, PhD, Vice President, Program Leader and Head of Research, Acumen Pharmaceuticals. “The degree of brain penetration we observed in cynomolgus monkeys, combined with preserved soluble amyloid beta oligomer selectivity and a clean hematological profile, exceeded our expectations and gives us strong confidence in the differentiated potential of our EBD program’s approach.”
Never Miss our Weekly Highlights HERE
Contact:
Click HERE to follow us on LinkedIn
